Use of low density lipoprotein particle number levels as an aid in statin treatment decisions for intermediate risk patients: a cost-effectiveness analysis

Table 4 Base-case results: Pairwise comparison

	Test-and-MST	Do-not-treat	Increment	Test-and-HST	MST	Increment
CVD events (n)	3787	3884	(97)	3177	3311	(134)
RVSC events (n)	3197	3294	(97)	2646	2727	(81)
Mild Adverse Events (n)	560	0	560	5600	5600	0
Severe Adverse Events (n)	4	0	4	37	37	0
Diabetes diagnoses (n)	36	0	36	442	368	74
Cost ($, Millions)	336.63	339.88	(3.25)	298.55	303.22	(4.67)
QALYs	460,162	460,118	44	460,119	460,004	115

Care strategies: do-not-treat, no statin therapy; test-and-MST, moderate-intensity statin therapy for those in the top decile of LDL-P levels; MST, moderate-intensity statin therapy for all; test-and-HST, high-intensity statin therapy those in the top decile of LDL-P levels and moderate-intensity statin therapy for all other; HST, high-intensity statin therapy for all
CVD cardiovascular disease, RVSC revascularization

ISSN: 1471-2261